Neurocrine Bio. (NBIX) PT Raised to $158 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Neurocrine Bio. (NBIX) PT Raised to $163 at Wedbush
August 1, 2024 12:16 PM EDTWedbush analyst Laura Chico raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $163.00 (from $152.00) while maintaining a Outperform rating.... More
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 50c
August 1, 2024 7:09 AM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.63, $0.50 better than the analyst estimate of $1.13. Revenue for the quarter came in at $580 million versus the consensus estimate of $547.1 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More